Vion Pharmaceuticals Regains NASDAQ Listing ... ( NEW HAVEN Conn. March 7 /- VionPh...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> NEWS

Vion Pharmaceuticals Regains NASDAQ Listing Compliance

Date:3/7/2008

NEW HAVEN, Conn., March 7 /PRNewswire-FirstCall/ -- Vion Pharmaceuticals, Inc. (Nasdaq Capital Market: VION) today announced that it had received notification from NASDAQ that the Company had regained compliance with Marketplace Rule 4310(c)(4) since the closing bid price of its Common Stock had traded at $1.00 per share or greater for at least ten consecutive business days.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a pivotal Phase II trial as a single agent in elderly patients with de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) as a single agent in small cell lung cancer, with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations,
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals

Post Your Comments:

[0] NICE guidelines ration affordable osteoporosis drugs [0] Menopause Often Means Worsening Cholesterol [0] China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 [1] New Board Gains Control of U.S. Shanghai Chemical Corporation [0] Surgery on beating heart thanks to robotic helping hand

Other Medicine News:Health News:Cogdell Spencer Announces Commencement of Common Stock Offering 2 Health News:Cogdell Spencer Announces Commencement of Common Stock Offering 3 Health News:Hanger Orthopedic Group, Inc. Announces Two Acquisitions Totaling $5.3 Million of Annual Net Revenue 2 Health News:LCA Hails US Court of Appeals Decision to Affirm Lower Court Ruling Tobacco Companies Guilty of Massive Fraud and Deception 2 Health News:LCA Hails US Court of Appeals Decision to Affirm Lower Court Ruling Tobacco Companies Guilty of Massive Fraud and Deception 3 Health News:National study finds youth baseball-related injuries down 25 percent 2 Health News:More Than 167,000 Fans Flock to Target Facebook Page Helping Donate $3 Million to Ten Charities 2 Health News:More Than 167,000 Fans Flock to Target Facebook Page Helping Donate $3 Million to Ten Charities 3 Health News:More Than 167,000 Fans Flock to Target Facebook Page Helping Donate $3 Million to Ten Charities 4 Health News:Strategic Diagnostics Appoints Kevin J. Bratton as Chief Financial Officer 2 Health News:Strategic Diagnostics Appoints Kevin J. Bratton as Chief Financial Officer 3 Health News:Strategic Diagnostics Appoints Kevin J. Bratton as Chief Financial Officer 4

Cogdell Spencer Announces Commencement of Common Stock Offering Hanger Orthopedic Group, Inc. Announces Two Acquisitions Totaling $5.3 Million of Annual Net Revenue LCA Hails US Court of Appeals Decision to Affirm Lower Court Ruling Tobacco Companies Guilty of Massive Fraud and Deception National study finds youth baseball-related injuries down 25 percent More Than 167,000 Fans Flock to Target Facebook Page Helping Donate $3 Million to Ten Charities Strategic Diagnostics Appoints Kevin J. Bratton as Chief Financial Officer

Breaking Medicine Technology:Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 2 Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 3 Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 4 Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer 2 Imagenetix Inc to Present at the 2009 RedChip New York Equities Conference 14251 1 Imagenetix Inc to Present at the 2009 RedChip New York Equities Conference 14251 2 Oncolytics Biotech 28R 29 Inc Announces Start of Enrolment in U S Phase 2 Melanoma Cancer Clinical Trial 5057 1 Oncolytics Biotech 28R 29 Inc Announces Start of Enrolment in U S Phase 2 Melanoma Cancer Clinical Trial 5057 2 Oncolytics Biotech 28R 29 Inc Announces Start of Enrolment in U S Phase 2 Melanoma Cancer Clinical Trial 5057 3 Oncolytics Biotech 28R 29 Inc Announces Start of Enrolment in U S Phase 2 Melanoma Cancer Clinical Trial 5057 4 Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associ 5055 1 Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associ 5055 2 Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associ 5055 3 Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associ 5055 4

[0] Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders [0] Mylan Receives Approval for Generic Version of Antiepileptic Keppra(R) 1000 mg [0] Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer

Other Medicine Technology:Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus 2 Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus 3 Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus 4 Journal of the American Dental Association Publishes Key Clinical Data for the Use of OraVerse(TM) a Local Anesthetic Reversal Agent 2 Journal of the American Dental Association Publishes Key Clinical Data for the Use of OraVerse(TM) a Local Anesthetic Reversal Agent 3

Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus Journal of the American Dental Association Publishes Key Clinical Data for the Use of OraVerse(TM) a Local Anesthetic Reversal Agent

Medicine Products:

Continuous Flow Cystoscopes Prolieve™ Thermodilatation System The Prostatron® System The Targis® System

Vion Pharmaceuticals Regains NASDAQ Listing ...( NEW HAVEN Conn. March 7 /- VionPh...),Health